Abstracts tagged "immunology"

Abstract Number: 1689 • ACR Convergence 2023
Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy
Lihi Eder¹, Xianwei Li², Sydney Thib³, Darshini Ganatra⁴, Liqun Diao² and Vinod Chandran⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: To characterize the relationships between peripheral blood immune cell profiles in patients with psoriatic arthritis (PsA) and (1) baseline clinical and imaging disease features;…
Abstract Number: 2290 • ACR Convergence 2023
Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model
Chrisanna Dobrowolski¹, Juan Pablo Diaz Martinez², Michelle Barraclough³, Roberta Kretzmann⁴, Sherief Marzouk⁴, Kathleen Bingham³, Lesley Ruttan⁵, Dorcas Beaton⁶, Joan Wither³, Carmela Tartaglia⁷, Patti Katz⁸, Mahta Kakvan⁹, Nicole Anderson¹⁰, Dennisse Bonilla³ and Zahi Touma⁴, ¹Icahn School of Medicine at Mount Sinai Hospital, New York, NY, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Institute for Work & Health, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University of California San Francisco, San Rafael, CA, ⁹University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is a common and often deleterious manifestation of systemic lupus erythematosus (SLE). CD is usually operationalized on the American College of…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 0201 • ACR Convergence 2023
Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months
Ioana Andreica¹, Gianna Chierergo², Stefania Reale², Benjamin Wilde³, Styliani Tsiami⁴, David Kiefer⁴, Philipp Sewerin⁴, Hilal Kavruk⁵, Dimitra Karagkiozidou², Barbara Guminski⁴, Andreas Kribben³, Xenofon Baraliakos⁶, Juergen Braun⁴ and Uta Kiltz⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Herne, Germany, ³Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁴Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Düsseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Herpes zoster (HZ) is common in the elderly, with a lifetime risk of 25%. The primary risk factors for HZ are advanced age and…
Abstract Number: 0959 • ACR Convergence 2023
Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis
Heetaek Yang¹, Rajan Bhandari¹, Saemi Han², Chanhyuk Park¹, Chen-Yu Wang², Emily Morris¹, Michael Whitfield¹ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease with multiple clinical and pathological manifestations including vascular involvement, immune activation, oxidative stress, and fibrosis. In…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 2337 • ACR Convergence 2023
Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA
Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing…
Abstract Number: 0059 • ACR Convergence 2023
GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice
Can Sungur¹, Li-ping Yang², Liang Shan¹ and wayne Yokoyama³, ¹Washington University, St. Louis, MO, ²Washington University in St. Louis, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO
Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV include HIV-associated inflammatory…
Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Emily G. Oakes¹, Katherine Buhler², Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Eilish Dillon¹, Jack Ellrodt¹, Jeong Yee¹, Deepak Rao¹, May Choi³ and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…
Abstract Number: 1723 • ACR Convergence 2023
3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity
Brendan Allen¹, Sabrina Fechtner², Meagan Chriswell³, Widian Jubair¹, M. Aaron Vrolijk¹, V. Michael Holers⁴ and kristine Kuhn¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado Anschutz SOM, Denver, CO, ⁴University of Colorado, Denver, CO
Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
Abstract Number: 2365 • ACR Convergence 2023
Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression
Vasuki Ranjani Chellamuthu¹, Maria Noviani², Ahmad bin Mohamed Lajam¹, Andrea Hsiu Ling Low² and Salvatore Albani¹, ¹Translational Immunology Institute, SingHealth, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation…
Abstract Number: 0060 • ACR Convergence 2023
Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Ting Wang¹, Philip Pemberton² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Redd Pharmaceuticals, Belmont, CA
Background/Purpose: Autoantibody-antigen complex-driven formation of neutrophil extracellular traps (NETs) is a major contributing factor to the pathophysiology and clinical manifestations of many different autoimmune diseases…
Abstract Number: 0258 • ACR Convergence 2023
Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation
Patricia Aires¹, Daniela Pioto¹, Maria Teresa TErreri² and Sandro Perazzio³, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil
Background/Purpose: A20, encoded by TNFAIP3, plays a critical role in NF-κB pathway regulation. A20 haploinsufficiency is a monogenic disorder form of Behçet's disease with a…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…

« Previous Page
1
…
5
6
7
8
9
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].